Exploring Biomarkers for Alzheimer’s Disease KE01-KE06
Dr. Neeti Sharma,
Assistant Professor, Symbiosis School of Biomedical Sciences, Symbiosis International University,
Gram-Lavale; Taluka- Mulshi, Pune-412115, Maharashtra, India.
Alzheimerâ€™s Disease (AD) is one of the most common form of dementia occurring in elderly population worldwide. Currently AÃŸ42, tau and p-tau in the cerebrospinal fluid is estimated for confirmation of AD. CSF which is being used as the potent source for biomarker screening is obtained by invasive lumbar punctures. Thus, there is an urgent need of minimal invasive methods for identification of diagnostic markers for early detection of AD. Blood serum and plasma serves as an appropriate source, due to minimal discomfort to the patients, promoting frequent testing, better follow-up and better consent to clinical trials. Hence, the need of the hour demands discovery of diagnostic and prognostic patient specific signature biomarkers by using emerging technologies of mass spectrometry, microarrays and peptidomics. In this review we summarize the present scenario of AD biomarkers such as circulatory biomarkers, blood based amyloid markers, inflammatory markers and oxidative stress markers being investigated and also some of the potent biomarkers which might be able to predict early onset of Alzheimerâ€™s and delay cognitive impairment.